Author
Listed:
- Catherine M. Shachaf
(Division of Medical Oncology, Departments of Medicine and Pathology)
- Andrew M. Kopelman
(Division of Medical Oncology, Departments of Medicine and Pathology)
- Constadina Arvanitis
(Division of Medical Oncology, Departments of Medicine and Pathology)
- Åsa Karlsson
(Division of Medical Oncology, Departments of Medicine and Pathology)
- Shelly Beer
(Division of Medical Oncology, Departments of Medicine and Pathology)
- Stefanie Mandl
(Stanford University)
- Michael H. Bachmann
(Stanford University)
- Alexander D. Borowsky
(University of California Davis Medical Center)
- Boris Ruebner
(University of California Davis Medical Center)
- Robert D. Cardiff
(University of California Davis Medical Center)
- Qiwei Yang
(Division of Medical Oncology, Departments of Medicine and Pathology)
- J. Michael Bishop
(University of California)
- Christopher H. Contag
(Stanford University)
- Dean W. Felsher
(Division of Medical Oncology, Departments of Medicine and Pathology)
Abstract
Hepatocellular carcinoma is generally refractory to clinical treatment1. Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with rapid loss of expression of the tumour marker α-fetoprotein, the increase in expression of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver stem cell marker cytokeratin 19. Using in vivo bioluminescence imaging we found that many of these tumour cells remained dormant as long as MYC remain inactivated; however, MYC reactivation immediately restored their neoplastic features. Using array comparative genomic hybridization we confirmed that these dormant liver cells and the restored tumour retained the identical molecular signature and hence were clonally derived from the tumour cells. Our results show how oncogene inactivation may reverse tumorigenesis in the most clinically difficult cancers. Oncogene inactivation uncovers the pluripotent capacity of tumours to differentiate into normal cellular lineages and tissue structures, while retaining their latent potential to become cancerous, and hence existing in a state of tumour dormancy.
Suggested Citation
Catherine M. Shachaf & Andrew M. Kopelman & Constadina Arvanitis & Åsa Karlsson & Shelly Beer & Stefanie Mandl & Michael H. Bachmann & Alexander D. Borowsky & Boris Ruebner & Robert D. Cardiff & Qiwei, 2004.
"MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer,"
Nature, Nature, vol. 431(7012), pages 1112-1117, October.
Handle:
RePEc:nat:nature:v:431:y:2004:i:7012:d:10.1038_nature03043
DOI: 10.1038/nature03043
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Anja Deutzmann & Delaney K. Sullivan & Renumathy Dhanasekaran & Wei Li & Xinyu Chen & Ling Tong & Wadie D. Mahauad-Fernandez & John Bell & Adriane Mosley & Angela N. Koehler & Yulin Li & Dean W. Felsh, 2024.
"Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma,"
Nature Communications, Nature, vol. 15(1), pages 1-13, December.
- Niranjan Venkateswaran & Roy Garcia & M. Carmen Lafita-Navarro & Yi-Heng Hao & Lizbeth Perez-Castro & Pedro A. S. Nogueira & Ashley Solmonson & Ilgen Mender & Jessica A. Kilgore & Shun Fang & Isabella, 2024.
"Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis,"
Nature Communications, Nature, vol. 15(1), pages 1-17, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:431:y:2004:i:7012:d:10.1038_nature03043. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.